Quick Answer
Vir Biotechnology, Inc. reported Diluted EPS of $3.16 per share (loss) for fiscal year 2025.
Vir Biotechnology, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.16 | +17.5% |
| 2024 | -$3.83 | +16.6% |
| 2023 | -$4.59 | -219.8% |
| 2022 | $3.83 | -3.3% |
| 2021 | $3.96 | +257.8% |
| 2020 | -$2.51 | +56.4% |
| 2019 | -$5.76 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.17 | +25.0% | -46.2% |
| June 30, 2025 | -$0.80 | +21.6% | +9.1% |
| March 31, 2025 | -$0.88 | -83.3% | +43.6% |
| September 30, 2024 | -$1.56 | -27.9% | -52.9% |
| June 30, 2024 | -$1.02 | +29.7% | -112.5% |
| March 31, 2024 | -$0.48 | +54.7% | +60.7% |
| September 30, 2023 | -$1.22 | -193.8% | +15.9% |
| June 30, 2023 | -$1.45 | -150.0% | -36.8% |
- Vir Biotechnology, Inc. showed an increase of +17.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Vir Biotechnology, Inc.’s diluted eps has grown by 45.1% (from $5.76 per share (loss) to $3.16 per share (loss)).
- The most recent figure is from Vir Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: